ADHERE-S (NIS Brilique)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03444012
Recruitment Status : Active, not recruiting
First Posted : February 23, 2018
Last Update Posted : November 22, 2018
Information provided by (Responsible Party):

Brief Summary:
noninterventional study investigating persistence and adherence on ticagrelor in ACS patients in Serbia

Condition or disease Intervention/treatment
ACS (Acute Coronary Syndrome) Drug: ticagrelor 90 mg

Study Type : Observational
Estimated Enrollment : 250 participants
Observational Model: Other
Time Perspective: Cross-Sectional
Official Title: Non-interventional Prospective Data Collection on Persistence and Adherence on Ticagrelor in ACS Adult Patients in Serbia
Actual Study Start Date : March 5, 2018
Estimated Primary Completion Date : September 30, 2019
Estimated Study Completion Date : September 30, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Ticagrelor

Intervention Details:
  • Drug: ticagrelor 90 mg
    persistence and adherence on ticagrelor in ACS patients

Primary Outcome Measures :
  1. duration (number of days) on ticagrelor therapy in patients with acute coronary syndrome [ Time Frame: 1 year (12 months) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult ACS patients

Inclusion Criteria:

  • ≥ 18 years of age
  • diagnosed with ACS - STEMI or NSTEMI or unstable angina, invasively or non-invasively treated
  • Patients already on treatment with ticagrelor at least for 1 month and no longer than 3 months prior to study initiation. Enrolment in this study must not be trigger for ticagrelor initiation.
  • read and signed the Informed Consent Form

Exclusion Criteria:

Any contraindications as per approved SmPC of Brilique

• Patients with life-threatening conditions which could disable patients to comply with scheduled visits and/or not able to fill in the patient questionnaires.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03444012

CHC Bezanijska Kosa
Belgrade, Serbia
CHC Zemun
Belgrade, Serbia
CHC Zvezdara
Belgrade, Serbia
Clinical Center of Serbia
Belgrade, Serbia
Institute for cardiovascular diseases, Dedinje
Belgrade, Serbia
Medical Military Academy
Belgrade, Serbia
Clinical Center Kragujevac
Kragujevac, Serbia
Clinical Center Nis
Nis, Serbia
Institute for cardiovascular diseases of Vojvodina
Sremska Kamenica, Serbia
Sponsors and Collaborators

Responsible Party: AstraZeneca Identifier: NCT03444012     History of Changes
Other Study ID Numbers: D5130R00052
First Posted: February 23, 2018    Key Record Dates
Last Update Posted: November 22, 2018
Last Verified: November 2018

Additional relevant MeSH terms:
Acute Coronary Syndrome
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs